Clinical trials: Rituximab, completed
Lymphoma, Non-Hodgkin's
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, plus the addition of Rituximab (which is a form of immunotherapy).
- Trial name
- NCT00143871
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can kill chronic lymphocytic leukemia (CLL) cells and are effective therapies for this disease.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT01269385
- Testing
- alemtuzumab, rituximab, PGG beta-glucan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Arthritis, Rheumatoid
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable…
- Trial name
- NCT02792699
- Testing
- ABP 798, Rituximab (US), Rituximab (EU)
- Where
- 55 sites in United States, Bulgaria and 4 more
- Volunteers
- 311 people
- Sponsor
- Amgen
DMARD Resistant Rheumatoid Arthritis
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
In this project the investigators decide to evaluate the efficacy and safety of half dose mabthera (it means 500 mg infusion two weeks apart) in conventional drug resistant cases of rheumatoid arthritis.
- Trial name
- NCT01593332
- Testing
- Rituximab
- Where
- Iran
- Volunteers
- 44 people
- Sponsor
- Mashhad University of Medical Sciences
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
This study was conducted to evaluate the complete response rate of Ibrutinib + R-CHOP in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
- Trial name
- NCT02670616
- Testing
- Ibrutinib, Rituximab, Cyclophosphamide
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Samsung Medical Center
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Non-Hodgkin's Lymphoma
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
In order to improve the clinical result of high-dose chemotherapy and autologous stem cell transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning regimen.
- Trial name
- NCT00336843
- Testing
- Zevalin-BuCyE
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Asan Medical Center
Leukemia, Lymphocytic
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance.
- Trial name
- NCT00327678
- Testing
- Rituximab, Imatinib Mesylate
- Where
- France
- Volunteers
- 1,080 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or…
- Trial name
- NCT00868608
- Testing
- Inotuzumab Ozogamicin (CMC-544)
- Where
- 42 sites in United States, Belgium and 7 more
- Volunteers
- 81 people
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone…
- Trial name
- NCT00877006
- Testing
- bendamustine, rituximab, vincristine
- Where
- 128 sites in United States, Australia and 5 more
- Volunteers
- 447 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Non-Hodgkins Lymphoma
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
In this trial, we will evaluate the feasibility, toxicity, and effectiveness ibritumomab tiuxetan, when incorporated into combination first-line treatment for follicular lymphoma.
- Trial name
- NCT00193440
- Testing
- Rituximab, CHOP, CVP
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Leukemia
Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00436904
- Testing
- Alemtuzumab, Rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Lymphoma
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- IDEC-C2B8 (NCT00064116)
- Testing
- rituximab, CHOP regimen
- Where
- 25 sites in Canada
- Volunteers
- 824 people
- Sponsor
- NCIC Clinical Trials Group
Chronic Lymphocytic Leukemia
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00381004
- Testing
- Cyclophosphamide, Fludarabine, Sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN).
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced
- Trial name
- NCT05894512
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Rheumatoid Arthritis
TL011 in Severe, Active Rheumatoid Arthritis Patients
The purpose of this study is to determine the safety and pharmacology of TL011 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01123070
- Testing
- TL011, anti CD20, for the treatment of rheumatoid arthritis, MabThera infusions
- Where
- 18 sites in Czechia, Hungary and 3 more
- Volunteers
- 54 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Prostate Cancer
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13 released by the tumor cells. B cells release lymphotoxin which drives malignant cell proliferation through the NFkB pathway.
- Trial name
- NCT01804712
- Testing
- rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Christopher Kane
Lymphoma, Chronic Lymphocytic Leukemia
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
The goal of this study is to characterize the safety, maximum tolerated dose (MTD) and preliminary efficacy profile of IPI-145 given in combination with rituximab, or bendamustine plus rituximab, to subjects with select…
- Conditions
- Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
- Trial name
- NCT01871675
- Testing
- IPI-145, Rituximab, Bendamustine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- SCRI Development Innovations, LLC
Follicular Lymphoma
Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy
Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan (Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalently bound to the chelating agent tiuxetan.
- Trial name
- FM+R-Z (NCT00859001)
- Testing
- FM+R, Zevalin (Ibritumomab Tiuxetan)
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- University of Bologna
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.